No profile data available.
Lineage Cell Therapeutics, Inc. (LCTX) is a healthcare company in the eye treatment pharmaceuticals industry, based in Carlsbad, United States, with about 72 full-time employees.
It reported revenue of $14.56 million for fiscal year 2025, up 53.2% from fiscal year 2024, and net income of -$63.53 million. Its market capitalization was $251.39 million as of October 9, 2026.
Figures from company filings and market data; latest fiscal year ended December 31, 2025; market data as of October 9, 2026.
, a clinical-stage biotechnology company, developing cell replacement therapies to treat serious medical conditions in the United States and internationally.
Lineage Cell Therapeutics reported $14.56 million in revenue for fiscal year 2025, up 53.2% from $9.50 million in fiscal year 2024.
$251.39 million as of October 9, 2026.
Listed companies of a similar size in the same industry (eye treatment pharmaceuticals) include Surrozen, Inc. (SRZN), Ocugen, Inc. (OCGN), EyePoint Pharmaceuticals, Inc. (EYPT), Opus Genetics, Inc. (IRD).